The treatment of lung cancer has been a problem in Indonesia. In Dharmais National Cancer Center Hospital, 541 lung cancer patients were hospitalized during 1993-1997, 344 of them were non small cell lung cancer in stage III & IV. Chemotherapy should have been indicated for them, but mainly due to financial reason only 54 of them could be so treated.
The treatment of lung cancer has been a problem in Indonesia. In Dharmais National Cancer Center Hospital, 541 lung cancer patients were hospitalized during 1993-1997, 344 of them were non small cell lung cancer in stage III & IV. Chemotherapy should have been indicated for them, but mainly due to financial reason only 54 of them could be so treated.
In spite of such a situation, a small number of them were able to provide cytostatic drugs for themself.
Pertamina Hospital, 40-50 nonsmall lung cancer patients were seen annually. The majority of the patients were the employees of Pertamina, for whom the cytostatic drugs were provided by the company.
This combination was relatively new, introduced in Jakarta in 1993, but it was not until 1994 that we began to use this combination for the treatment of lung cancer in Dharmais Hospital and since 1996 in 1 2 3 Paclitaxel in combination with carboplatin were among Pertamina Hospital. According to literature • • this of the regimens that were chosen for these patients. In
* Dharmais National Cancer Center Hospital, Faculty of
Medicine, University of Indonesia, Jakarta, Indonesia ** Pertamina Central General Hospital, Jakarta, Indonesia combination is quite effective for nonsmall cell lung cancer with tolerable side effects. To evaluate the usefulness of this combination for our patients, we studied retrospectively the outcome of treatment using this combination on lung cancer ;'atients in both hospital. 
MATERIAL AND METHODS

RESULTS
Nineteen patients were recruited for evaluation. There were 12 males and females, the age ranged between 42 years and 73 years (median : 57 yrs). Fourteen of them were stage IV disease, 4 stage IIIB disease and one had stage IIIA disease. Histologic diagnoses were squamous carcinoma in 4 patients, adenocarcinoma in 14 patients and adenosquamous carcinoma in I patient. Seventeen patients completed 6 cycles of chemotherapy, one had only 3 cycles and one had 4 cycles. The shortest follow up period was 4 months and the longest was 35 months after the start of chemotherapy. Two patients are still alive at 22 and 23 months after the start of chemotherapy. Objective response was seen in 12 ou t of 19 patients 63%. No patients had complete response, twel ve had partial response. Two patients ( 10,5%) showed stable disease and progression was seen in 5 patients (26,3%), as seen in Table 1 . was given on December 31si, 1998 to check which patients were surviving The details of treatment were as follows :
hydration with saline solution before the administration of cytostatic premedication with dexamethason, ondansetron and diphenhydramine paclitaxel was given over 3 hrs infusion, the dose being 135 mg/m2 at the beginning of the study, later being 175 mg/m2 or 200 mg/m2. (71%) and progressive disease in 4/14 (29%), as seen in Table 2 . Among these patients , one year survival rate was 6 out of 14 patients (43%); the median survival time was 14 months (see Figure 2) . All patients had nausea and vornitting grade 1-2, none had grade 3-4. Alopecia was seen in all patients. No renal or cardiac toxicity was found. Neurotoxicity such as peripheral neuropathy was not well recorded, but were seen in some patients, none of them had grade 3 or 4. Serious side effects, namely grade 3 thrombocytopenia were seen in 5 patients (26%), 1 patient (5%) and 2 patients (11%), respectively (Table 3) .
Paclitaxel and carboplatin combination has been studied by many investigators with various results, as seen in Table 4 4 used combinations of paclitaxel with carboplatin dosed to different targeted AUC-s, also had PR of over 50%. Our result which was surprisingly high , may be due to more selected patients; as this is a retrospective report of patients after completing the treatment and follow up. (71%) and progressive disease in 4/14 (29%), as seen in Table 2 . Among these patients, one year survival rate was 6 ou t of 14 patients (43%); the median survival time was 14 months (see Figure 2) . All patients had nausea and vomitting grade 1-2, none had grade 3-4. Alopecia was seen in all patients. No renal or cardiac toxicity was found. Neurotoxicity such as peripheral neuropathy was not well recorded, but were seen in some patients, none of them had grade 3 or 4. Serious side effects, namely grade 3 thrombocytopenia were seen in 5 patients (26%), 1 patient (5%) and 2 patients (11%), respectively (Table 3) .
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Paclitaxel and carboplatin combination has been studied by many investigators with various results, as seen in Table 4 paclitaxel with carboplatin dosed to different targeted AUC-s, also had PR of over 50%. Our result which was surprisingly high, may be due to more selected patients; as this is a retrospective report of patients after completing the treatment and follow up.
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